Spantide I

Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3].

Product Specifications

CAS Number

[91224-37-2]

UNSPSC

12352209

Target

Neurokinin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/spantide-i.html

Purity

99.72

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=CC=C3)NC([C@H](NC([C@H](CCC(N)=O)NC([C@H](CCC(N)=O)NC([C@H]4N(CCC4)C([C@H](CCCCN)NC([C@H]5N(CCC5)C([C@H](N)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)CC6=CNC7=CC=CC=C67)=O)=O)=O)=O

Molecular Formula

C75H108N20O13

Molecular Weight

1497.79

References & Citations

[1]J C Beaujouan, et al. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol. 1993 Mar;108 (3) :793-800.|[2]M Zubrzycka, et al. Comparison of antagonistic properties of substance P analogs, spantide I, II and III, on evoked tongue jerks in rats. Endocr Regul. 2000 Mar;34 (1) :13-8.|[3]Linda D Hazlett, et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest Ophthalmol Vis Sci. 2007 Feb;48 (2) :797-807.